NCT04302025 2026-04-03A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Genentech, Inc.Phase 2 Recruiting99 enrolled
NCT06528691 2026-03-23Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsSt. Jude Children's Research HospitalPhase 2 Recruiting52 enrolled